Rosuvastatin: Beyond the cholesterol-lowering effect

详细信息    查看全文

• 作者：Francesca Cortese^a ; ^{francescacortese@hotmail.it" class="auth_mail" title="E-mail the corresponding author} ; Michele Gesualdo^a ; Annamaria Cortese^b ; Santa Carbonara^a ; Fiorella Devito^a ; Annapaola Zito^a ; Gabriella Ricci^a ; Pietro Scicchitano^a ; Marco Matteo Ciccone^a
• 关键词：Rosuvastatin (PubChem CID ; 446157) ; Cholesterol (PubChem CID ; 5997) ; Mevalonate (PubChem CID ; 4478250) ; Farnesylpyrophosphate (PubChem CID ; 44134714) ; Geranylgeranylpyrophosphate (PubChem CID ; 44134732) ; Nitric Oxide (PubChem CID ; 145068) ; Coenzyme Q10 (PubChem CID ; 5281915)
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：107
• 期：Complete
• 页码：1-18
• 全文大小：2549 K

文摘

Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. When compared to other molecules of the same class, it shows high efficacy in the improvement of lipid profile, and, thanks to its non-cholesterol-lowering actions (anti-inflammatory, antioxidant and antithrombotic), represents a crucial tool for cardiovascular primary and secondary prevention.

Moreover, recent data highlight rosuvastatin beneficial effects in several other fields. In this manuscript we analyzed literature sources in order to better define rosuvastatin features and discuss some critical issues.